A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
Status:
Completed
Trial end date:
2019-03-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of ustekinumab as measured by a
reduction in disease activity for subjects with active Active Systemic Lupus Erythematosus
(SLE - chronic disorder of connective tissue in which there can be skin rash, arthritis,
kidney problems, and anemia, among other problems).